Item 8.01 Other Events. On April 8, 2026, MacroGenics, Inc. (the “ Company”) issued a press release announcing that the U. S. Food and Drug Administration has removed the partial clinical hold on the Company’s Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with gynecologic cancers. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release dated A pril 8, 2026 ────────────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 8, 2026 MACROGENICS, INC. ───────────────────────────────────────────────────────────────────────────────────────────── By: /s/ Jeffrey Peters